Internal Medicine, Hematology & Oncology · Hampton, VA
NPI
1245676477
Since 2013
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3000 Coliseum Dr Ste 104
Hampton, VA, 23666
Phone (757) 827-9400
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.6M
212,521 services
Medicare patients, 2024
1,088
Average age 75
Drug cost, 2024
$5.8M
2,175 prescriptions
Company payments, 2025
$338
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David J Kobulnicky was code J9025 (injection, azacitidine, 1 mg), 27,900 times for 19 patients. In total David J Kobulnicky billed 212,521 services in 201 codes, and Medicare paid $4.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9025 Injection, azacitidine, 1 mg | Office | 27,900 | 19 | $0.30 | $8,369 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 24,120 | 15 | $38.63 | $932K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 18,320 | 17 | $2.34 | $43K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 18,200 | 21 | $44.61 | $812K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 8,940 | 17 | $36.87 | $330K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,600 | 22 | $0.11 | $753 |
| J9267 Injection, paclitaxel, 1 mg | Office | 6,144 | 13 | $0.08 | $492 |
| J0897 Injection, denosumab, 1 mg | Office | 4,620 | 36 | $19.90 | $92K |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 3,420 | 17 | $16.05 | $55K |
| 85025 Blood Count | Office | 2,784 | 613 | $7.56 | $21K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,755 | 91 | $0.09 | $246 |
| 80053 Clinical Chemistry | Office | 2,308 | 576 | $10.27 | $24K |
| 82784 Immunoassay | Office | 1,416 | 141 | $8.99 | $13K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,030 | 37 | $0.71 | $727 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 939 | 425 | $12.31 | $12K |
By year: 2022 $3.6M for 205,926 services; 2023 $4.8M for 242,474 services; 2024 $4.6M for 212,521 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,784 | 613 | $7.56 | $21K |
| 80053 Clinical Chemistry | 2,308 | 576 | $10.27 | $24K |
| 82784 Immunoassay | 1,416 | 141 | $8.99 | $13K |
| 36415 Venipuncture Blood Collection | 775 | 306 | $8.62 | $6,679 |
| 83520 Immunoassay | 764 | 145 | $16.76 | $13K |
| 88185 Surgical Pathology Examination | 757 | 30 | $17.15 | $13K |
| 82728 Clinical Chemistry | 495 | 245 | $13.34 | $6,601 |
| 83550 Clinical Chemistry | 486 | 244 | $8.55 | $4,157 |
| 83540 Clinical Chemistry | 485 | 243 | $6.33 | $3,069 |
| 83615 Clinical Chemistry | 474 | 187 | $5.85 | $2,773 |
Medicare prescription drug claims, 2024
In 2024, the drug David J Kobulnicky prescribed most often to Medicare patients was Anastrozole, with 136 prescriptions and refills. In total David J Kobulnicky wrote 2,175 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 136 | 315 | 31 | $1,525 |
| Acyclovir Generic | 127 | 234 | 39 | $2,089 |
| Eliquis Apixaban | 79 | 129 | 28 | $67K |
| Dexamethasone Generic | 69 | 82 | 35 | $1,258 |
| Ondansetron Hcl Generic | 68 | 68 | 41 | $34K |
| Potassium Chloride Generic | 62 | 87 | 15 | $1,144 |
| Imbruvica Ibrutinib | 57 | 57 | Under 11 | $789K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 55 | 55 | 25 | $2,170 |
| Levothyroxine Sodium Generic | 51 | 95 | 21 | $639 |
| Hydroxyurea Generic | 47 | 117 | 16 | $737 |
| Furosemide Generic | 46 | 84 | 17 | $270 |
| Prednisone Generic | 44 | 57 | 23 | $323 |
| Prochlorperazine Maleate Generic | 44 | 46 | 32 | $630 |
| Xarelto Rivaroxaban | 39 | 69 | 13 | $38K |
| Gabapentin Generic | 34 | 39 | Under 11 | $292 |
Brand drugs: - claims; generic drugs: 1,578 claims; opioid claims: 175.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David J Kobulnicky $338 ($338 in general payments such as food, travel and fees) from 7 companies. The largest payer was Array Biopharma Inc with $150.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.